// App-Quantinova.ai

752 : Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA): A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study

Researchers

Presenter

  • Nichola Cooper

Principal Investigators

  • Robert P. Numerof

  • Sandra Tong

  • David J. Kuter

Medical Centers

  • Hammersmith Hospital, Imperial College, London, United Kingdom

  • Threshold Pharmaceuticals, Inc., South San Francisco, CA

  • Nephrology Division, Massachusetts General Hospital, Boston, MA

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Cardiovascular (CVS)

Disease

  • Chronic Lymphocytic Leukemia

  • Lupus

  • Autoimmune hemolytic anemia

  • Immune thrombocytopenia

  • Thrombocytopenia

  • Hypertension

  • Scleroderma

  • Coronavirus disease

  • Anemia

Biomarkers

  • Neutrophil count

  • Cluster of differentiation 79A

  • Dopamine transporter

  • Haptoglobin

  • Immunoglobulin G

  • Lactate dehydrogenase

  • Red Blood Cells

  • Platelet count

Drug/Treatment

  • Fostamatinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02612558

  • NCT03764618

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved